Brind.

Novartis reports positive Phase III results for remibrutinib in multiple sclerosis

1 report, 1 independent Updated Oct 23
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Novartis presented Phase III results for remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, in relapsing multiple sclerosis. The drug reduced annualized relapse rates by 35% in one study and 31.2% in another compared to teriflunomide. Global regulatory filings are currently underway, with a U.S. submission anticipated by the end of the year.

From tickerreport.com

Why it matters

Some supportBrind's analysis of the reports

The positive results suggest remibrutinib could be positioned as an oral treatment option for MS that provides disease control without chronic B-cell depletion. The trials, which included input from Heinz Wiendl of the University of Freiburg, showed significant reductions in disability progression and MRI lesion activity.

From tickerreport.com

Who's involved

  • NovartisDeveloped and presented Phase III results for remibrutinib.
  • University of FreiburgUniversity where Heinz Wiendl holds a professorship and was involved in the REMODEL studies.
  • Heinz WiendlGerman neurologist who served on the REMODEL steering committee.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped